TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen announced a webcast on January 15, 2026 to discuss Phase 2 clinical trial data from the OCU410 ArMaDa trial, featuring leading ophthalmologists and company executives. The presentation will cover one-year follow-up data from the first half of patients treated with the modifier gene therapy for blindness diseases.

Insights
CSCO   positive

Nominated in categories including Digital Divide Impact, Network Security, and Wireless Innovation, showcasing comprehensive technological solutions


OCGN   positive

The company is presenting clinical trial data from a Phase 2 study, indicating progress in its gene therapy pipeline. The webcast featuring prominent clinical investigators and discussion of one-year patient data suggests meaningful results worth presenting to stakeholders and the investment community.